16
Participants
Start Date
February 16, 2019
Primary Completion Date
November 26, 2021
Study Completion Date
November 26, 2021
allo-APZ2-EB
intravenous infusion of allo-APZ2-EB
EB-Haus Austria; Salzburger Landeskliniken (SALK); Paracelsus Medizinische Privatuniversität Salzburg (PMU), Salzburg
University of Minnesota, Masonic Cancer Center and Medical Center, Minneapolis
Hôpital Saint-Louis; Département de dermatologie, Paris
Department of Dermatology, Medical Center-University of Freiburg, Freiburg im Breisgau
King's College London; St John's Institute of Dermatology;, London
Great Ormond Street Hospital; Dermatology Department, London
Collaborators (2)
FGK Clinical Research GmbH
INDUSTRY
Granzer Regulatory Consulting & Services
OTHER
Ticeba GmbH
INDUSTRY
RHEACELL GmbH & Co. KG
INDUSTRY